Viromed Medical AG Announces Promising Results for PulmoPlas® in ICU Pneumonia Treatment

Viromed Medical AG has disclosed encouraging results from a study focused on PulmoPlas®, a cold plasma device aimed at treating ventilator-associated pneumonia (VAP) in ICU patients. VAP is a severe lung infection with a mortality rate of 10-13%. The study, led by Prof. Hortense Slevogt, demonstrated that PulmoPlas® effectively eliminates bacteria in the respiratory tract within 30-90 seconds, including resistant strains like MRSA, without harming lung tissue.

Uwe Perbandt, CEO of Viromed, emphasized the potential global impact of this treatment in reducing hospital stays and saving lives. The company plans to seek regulatory approval from the Federal Institute for Drugs and Medical Devices based on these findings, with detailed results expected by mid-2025.

A second part of the study, exploring PulmoPlas® for VAP prevention, is ongoing, with outcomes anticipated in 2026.